[Paclitaxel for treatment of advanced breast cancers].
Ito
Y
Y
Department of Medical Oncology, Cancer Institute Hospital.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000008:administration & dosage; D004342:Drug Hypersensitivity; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic; D004317:Doxorubicin; D000068878:Trastuzumab; D017239:Paclitaxel